Zerion is a pharmaceutical development company improving the formulation of poorly soluble drugs (oral solid dosage forms) that are currently not reaching their therapeutic potential. Through the use of our proprietary formulation platform, Dispersome®️, we aim to develop new treatment options for patients across all therapeutic areas. We are focused on improving existing drug products by building an internal pipeline. In addition, we are partnering with originator pharma companies to enable their early stage drug molecules. Using our enabling excipient-based technology we strive to improve the lives of patients around the world. Zerion was established in 2019 as a spinout company from the University of Copenhagen based on almost a decade of research.